Addex Therapeutics Ltd. (ADXN) stock
Close on Nov 13, 2026Market cap $83.36KP/E –Yield –
Addex Therapeutics Ltd. saw revenue fall 92.6% to CHF 29.97K over fiscal 2025. Free cash flow was -CHF 2.17M. At the latest close the market valued the company at CHF 68.29K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- CHF 68.29K
- P/E ratio
- –
- Price to sales
- 2.28
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3179.30%
Fundamentals
- Revenue
- CHF 29.97K
- EPS, diluted
- -0.06 CHF
- Free cash flow
- -CHF 2.17M
- Diluted shares
- 123M
Trading
- Previous close
- $5.29
- Open
- $4.75
- Day's range
- $3.75 – $5.00
- Volume
- 560,116
- Average volume (20 days)
- 1,204,833
- Beta (5 years)
- 0.90
- RSI (14 days)
- 59.4
- Volatility (1 year)
- 117.6%
- Relative volume
- 1.33×
- WACC
- 9.6%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADXN | S&P 500 | Difference | ADXN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +34.9% | -3.0% | +37.9 pts | ||
| 3 months | -31.8% | -2.8% | −29.0 pts | ||
| Year to date | -47.4% | +11.5% | −58.9 pts | ||
| 1 year | -52.8% | +13.5% | −66.3 pts | ||
| 3 years | -25.0% | +77.7% | −102.7 pts | -9.1% | +21.1% |
| 5 years | -97.4% | +72.6% | −170.0 pts | -51.7% | +11.5% |
Ten years at a glance
Fiscal years 2016 to 2025, CHF
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Addex Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Addex Therapeutics
Pharmaceutical Preparations
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on discovering and developing orally available small molecule drug candidates. The company specializes in allosteric modulators targeting G-protein coupled receptors to treat conditions with high unmet medical needs. Its proprietary development pipeline includes dipraglurant for brain injury and post-stroke sensorimotor recovery, ADX71149 for evaluated neurological indications, and positive allosteric modulator programs targeting chronic cough and substance use disorders. Rather than selling directly to commercial consumers, the company advances candidates through internal programs or licenses them to pharmaceutical partners, such as Indivior.
Company profile, executives and historyAddex Therapeutics stock: common questions
What is Addex Therapeutics's stock price?
ADXN closed at $4.06 on Nov 13, 2026, down 23.25% on the day.
What is Addex Therapeutics's market cap?
Addex Therapeutics was worth $83.36K at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ADXN's P/E ratio?
Addex Therapeutics lost money over fiscal 2025 (diluted EPS -0.06 CHF), so it has no meaningful P/E ratio.
How much revenue does Addex Therapeutics make?
Addex Therapeutics reported revenue of CHF 29.97K for fiscal 2025, down 92.6% from a year earlier.
Does Addex Therapeutics pay a dividend?
No. Addex Therapeutics has not paid a cash dividend over the last twelve months.
How has ADXN stock performed over the past year?
Including dividends, ADXN returned -52.8% over the past year, against +13.5% for the S&P 500.
Who are Addex Therapeutics's competitors?
Companies most similar to Addex Therapeutics by business, industry and size include KPRX, KZIA, CNBX, JUNS, IXHL.
See a number that looks wrong?